Cercar
01/04/2023
Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years
Falkenhain-Lopez, D, Muniesa, C, Estrach, MT, Morillo-Andujar, M, Penate, Y, Acebo, E, Pujol, RM, Garcia-Muret, MP, Machan, S, Medina, S, Botella-Estrada, R, de Misa, RF, Blanes, M, Florez, A, Perez-Paredes, G, Izu, R, Yanguas, I, Silva-Diaz, E, Perez-Ferriols, A, Prieto-Torres, L, Zayas, A, Parera-Amer, ME, Perez, A, Aspe, L, Roman, C, Sanchez-Caminero, MP, Bassas-Vila, J, Dominguez-Aunon, JD, Calzado, L, Navedo, M, Ortiz-Prieto, A, Servitje, O, Polo-Rodriguez, I, Torres, I, Hernandez-Hernandez, MN, Mitxelena-Eceiza, J, Garcia-Vazquez, A, Garcia-Doval, I, Ortiz-Romero, PL. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermo-Sifiliograficas. 2023; 114(4)DOI:10.1016/j.ad.2022.11.013. PMID:36848951. IF:(Q/D).
15/03/2023
Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care
Escale-Besa, A, Yelamos, O, Vidal-Alaball, J, Fuster-Casanovas, A, Catalina, QM, Borve, A, Aguilar, RAE, Fusta-Novell, X, Cubiro, X, Rafat, ME, Lopez-Sanchez, C, Marin-Gomez, FX. Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care. Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-31340-1. PMID:36922556. IF:3.800(Q1/2D).
10/03/2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023)
Egeberg A., Merola J.F., Schaekel, K, Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths, CEM. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023). Frontiers in Medicine. 2023; 10DOI:10.3389/fmed.2023.1171132. PMID:36974067. IF:3.100(Q1/2D).
22/02/2023
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Kokolakis, G, Warren, RB, Strober, B, Blauvelt, A, Puig, L, Morita, A, Gooderham, M, Korber, A, Vanvoorden, V, Wang, M, de Cuyper, D, Madden, C, Gomez, NN, Lebwohl, M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(3)DOI:10.1093/bjd/ljac089. PMID:36751950. IF:11.000(Q1/1D).
01/02/2023
BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis
Fusta-Novell, X, Garcia-Herrera, A, Yelamos, O. BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis. Actas Dermo-Sifiliograficas. 2023; 114(2)DOI:10.1016/j.ad.2021.10.022. PMID:36216154. IF:(Q/D).
01/01/2023
Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives
Camina-Conforto, G, Mateu-Arrom L., López-Ferrer A., Puig L.. Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives. Patient Preference and Adherence. 2023; 17DOI:10.2147/PPA.S350760. PMID:37408843. IF:2.000(Q2/4D).
01/01/2023
Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain
Artime E., Serra E., Mert C., Díaz-Cerezo S., Huete T., Hernández-Subirá I., Lledo-Bryant L., Sicras-Mainar A.. Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain. Actas Dermo-Sifiliograficas. 2023; 114(1)DOI:10.1016/j.ad.2022.08.025. PMID:36368579. IF:(Q/D).
01/01/2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober B., Paul C., Blauvelt A., Thaçi D., Puig L., Lebwohl M., White K., Vanvoorden V., Deherder D., Gomez N.N., Eyerich K.. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(3)DOI:10.1016/j.jaad.2023.04.063. PMID:37182701. IF:12.800(Q1/1D).